Pacira BioSciences' Free Cash Flow rose 1432.13% to $57.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.2 million, marking a year-over-year decrease of 3582.02%. This contributed to the annual value of $178.8 million for FY2024, which is 2814.94% up from last year.
Per Pacira BioSciences' latest filing, its Free Cash Flow stood at $57.0 million for Q3 2025, which was up 1432.13% from $9.3 million recorded in Q2 2025.
Pacira BioSciences' Free Cash Flow's 5-year high stood at $57.0 million during Q3 2025, with a 5-year trough of -$992000.0 in Q1 2021.
Over the past 5 years, Pacira BioSciences' median Free Cash Flow value was $36.5 million (recorded in 2022), while the average stood at $31.9 million.
In the last 5 years, Pacira BioSciences' Free Cash Flow crashed by 9224.81% in 2021 and then skyrocketed by 242953.63% in 2022.
Quarter analysis of 5 years shows Pacira BioSciences' Free Cash Flow stood at $14.0 million in 2021, then skyrocketed by 160.13% to $36.5 million in 2022, then rose by 25.29% to $45.8 million in 2023, then crashed by 32.26% to $31.0 million in 2024, then skyrocketed by 83.67% to $57.0 million in 2025.
Its Free Cash Flow stands at $57.0 million for Q3 2025, versus $9.3 million for Q2 2025 and $26.9 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value